497.05

+2.64%↑

SANES

10.984

+4.23%↑

SAF

315.8

+5.41%↑

BBVA

20.28

+3.79%↑

BNP

94.03

+3.79%↑

497.05

+2.64%↑

SANES

10.984

+4.23%↑

SAF

315.8

+5.41%↑

BBVA

20.28

+3.79%↑

BNP

94.03

+3.79%↑

497.05

+2.64%↑

SANES

10.984

+4.23%↑

SAF

315.8

+5.41%↑

BBVA

20.28

+3.79%↑

BNP

94.03

+3.79%↑

497.05

+2.64%↑

SANES

10.984

+4.23%↑

SAF

315.8

+5.41%↑

BBVA

20.28

+3.79%↑

BNP

94.03

+3.79%↑

497.05

+2.64%↑

SANES

10.984

+4.23%↑

SAF

315.8

+5.41%↑

BBVA

20.28

+3.79%↑

BNP

94.03

+3.79%↑

Home・Akcijų sąrašas・AB Science SA

AB Science SA

Uždarymo kaina

1.136 -4.7

Pirkti Parduoti

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

1.104

Max

1.162

Pagrindiniai rodikliai
By Trading Economics
Pajamos	-5.2M
Pardavimai	515K
Pelno marža	-1,005.243
Darbuotojai	36
EBITDA	-2.5M

Dividendai
By Dow Jones
Kitas uždarbis	2026-05-11

Rinkos statistika
By TradingEconomics
Rinkos kapitalizacija	79M
Ankstesnė atidarymo kaina	5.84
Ankstesnė uždarymo kaina	1.136

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Bearish Evidence

1.426 / 1.448 Palaikymas ir pasipriešinimas

AB Science SA Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-04-17 20:26; UTC

Įsigijimai, susijungimai, perėmimai

UCB to Buy Neurona Therapeutics for Up to $1.15 Billion

2026-04-17 18:15; UTC

Svarbiausios naujienos

Fed's Waller: Prolonged Iran Conflict Could Block Path to Rate Cuts

2026-04-17 16:49; UTC

Svarbiausios naujienos

Week Ahead for FX, Bonds: U.S. Retail Sales, PMI -2-

2026-04-17 16:49; UTC

Svarbiausios naujienos

Week Ahead for FX, Bonds: U.S. Retail Sales, PMI Data Due as Focus Remains on Middle East

2026-04-17 22:58; UTC

Uždarbis

Grupo Aeroportuario Del Pacifico: Announces Filing of 2025 Annual Report and Form 20-F

2026-04-17 21:32; UTC

Rinkos pokalbiai

Cerebras IPO Adds to Big Year For AI Firms Going Public -- Market Talk

2026-04-17 21:22; UTC

Rinkos pokalbiai

Global Forex and Fixed Income Roundup: Market Talk

2026-04-17 21:22; UTC

Rinkos pokalbiai

Moody's Downgrades Belgium to A1 -- Market Talk

2026-04-17 20:52; UTC

Uždarbis

Schwab Investors Get Spooked by JPMorgan's AI Strategy. The Big Worry Is Cash Sweeps. -- Barrons.com

2026-04-17 20:50; UTC

Rinkos pokalbiai

Uždarbis

Įsigijimai, susijungimai, perėmimai

Tech, Media & Telecom Roundup: Market Talk

2026-04-17 20:50; UTC

Rinkos pokalbiai

Basic Materials Roundup: Market Talk

2026-04-17 20:29; UTC

Uždarbis

These Stocks Are Today's Movers: Royal Caribbean, Dow Inc., Netflix, Intel, Albemarle, Autoliv, Alcoa, and More -- Barrons.com

2026-04-17 20:11; UTC

Įsigijimai, susijungimai, perėmimai

UCB to Buy Neurona Therapeutics for Up to $1.15B

2026-04-17 19:34; UTC

Rinkos pokalbiai

Uždarbis

Įsigijimai, susijungimai, perėmimai

Global Equities Roundup: Market Talk

2026-04-17 19:34; UTC

Rinkos pokalbiai

Uždarbis

Įsigijimai, susijungimai, perėmimai

Analysts See Netflix's Deal Commentary as Notable -- Market Talk

2026-04-17 19:31; UTC

Rinkos pokalbiai

Svarbiausios naujienos

Oil Futures Fall on Reopening of Strait of Hormuz -- Market Talk

2026-04-17 19:26; UTC

Rinkos pokalbiai

U.S. Natural Gas Futures Edge Up -- Market Talk

2026-04-17 19:21; UTC

Rinkos pokalbiai

Albemarle's Outperformance Belies Longer-Term Risks -- Market Talk

2026-04-17 19:15; UTC

Rinkos pokalbiai

Danaher Seen Rebounding in 2H After Tools-Sector Weakness -- Market Talk

2026-04-17 19:07; UTC

Rinkos pokalbiai

Danaher Faces Tough Comparative but Long‑Term Story Intact -- Market Talk

2026-04-17 18:57; UTC

Svarbiausios naujienos

U.S. Stocks Surge on Hope Iran War Nearing End. Foreign Leaders Have a More Sober View. -- Barrons.com

2026-04-17 18:53; UTC

Įsigijimai, susijungimai, perėmimai

UCB Expects 2026 Adjusted Ebitda Growth in High Single-Digit to Mid-Teens Percentage Range at Constant Exchange Rates

2026-04-17 18:53; UTC

Įsigijimai, susijungimai, perėmimai

UCB 2026 Rev Guidance Unchanged

2026-04-17 18:52; UTC

Įsigijimai, susijungimai, perėmimai

UCB: Neurona Deal to Include $650M Upfront and Up to $500M in Potential Future Milestones

2026-04-17 18:52; UTC

Įsigijimai, susijungimai, perėmimai

UCB to Acquire Neurona Therapeutics for Up to $1.15B Including Potential Milestones

2026-04-17 18:14; UTC

Rinkos pokalbiai

Svarbiausios naujienos

Precious Metals Close Higher as Stronger Demand Eyed -- Market Talk

2026-04-17 18:00; UTC

Svarbiausios naujienos

Fed's Waller: Quick Resolution in Middle East Could Allow Cuts Later This Year

2026-04-17 18:00; UTC

Svarbiausios naujienos

Fed's Waller: Job Losses May Not Signal Recession Amid Demographic Changes

2026-04-17 17:31; UTC

Rinkos pokalbiai

Svarbiausios naujienos

U.S. Oil Rig Count Down By 1 at 410 -- Market Talk

2026-04-17 17:26; UTC

Rinkos pokalbiai

Uždarbis

Netflix's Ability to Grow Engagement Seen as Up in the Air -- Market Talk

Akcijų palyginimas

Kainos pokytis

AB Science SA Prognozė

Bendras įvertinimas

By TipRanks

0 ratings

Pirkti

Laikyti

Parduoti

Remiantis 0 analitikų, pateikusių AB Science SA akcijų reitingus – Dist per pastaruosius 3 mėnesius.

Techninis įvertinimas

By Trading Central

1.426 / 1.448Palaikymas ir pasipriešinimas

Recent bearish events outweigh bullish events.

Bullish events outweigh bearish events.

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

Apie bendrovę AB Science SA

AB Science S.A., a clinical-stage company, designs and develops novel drugs to various diseases with high unmet medical needs for inflammatory diseases, pathologies affecting peripheral and central nervous system, and cancers in France. The company's lead compound is the masitinib, a tyrosine kinase inhibitor which is in Phase III clinical trials for the treatment of amyotrophic lateral sclerosis, indolent systemic mastocytosis, severe asthma, progressive forms of multiple sclerosis, first line pancreatic cancer with pain, alzheimer's disease, and metastatic castrate-resistant prostate cancer, as well as in Phase II clinical trial to treat Covid-19. It also developing AB8939, a microtubule destabiliser for acute myeloid leukemia. The company markets its masitinib under the Masivet brand in Europe. AB Science S.A. was incorporated in 2001 and is headquartered in Paris, France.